• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bausch+Lomb launches $1.4B offering to finance XIIDRA eye drop buy

September 11, 2023 By Sean Whooley

Bausch + Lomb (1)Bausch + Lomb (NYSE:BLCO) announced today that it launched an offering worth $1.4 billion in new senior secured notes.

The company intends to offer the notes, due 2028, and to enter into an incremental term loan facility. Both moves aim to support the financing of the company’s pending acquisition of XIIDRA. Bausch + Lomb expects to borrow $500 million in new term B loans under the loan facility.

The company agreed to buy the non-steroid eye drops and rights to an associated delivery device from Novartis for $2.5 billion in June.

XIIDRA (lifitegrast ophthalmic) solution 5% has approval to treat the signs and symptoms of dry eye disease (DED). It focuses on inflammation associated with dry eye. The acquisition complements Bausch + Lomb’s existing dry eye portfolio, which includes eye and contact lens drops. It features the recently approved MIEBO eye drop for DED, which works differently than XIIDRA.

Bausch + Lomb expects the net proceeds to fund the XIIDRA acquisition, and pay fees and expenses related to closing. The company also earmarked funds for fees related to the offering of notes, the loan borrowing and general corporate purposes. That may include the repayment of existing debt, according to a news release.

Closing of the term loan facility remains contingent upon the completion of the acquisition. Bausch + Lomb expects that to occur concurrently with the acquisition’s closing at or around the end of September 2023. If the acquisition fails to take place on or prior to Sept. 30, 2024, or other specified events don’t occur, the escrow issuer will be required to redeem the notes at such time at a redemption price equal to the principal amount of the notes plus accrued and unpaid interest.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: bausch&lomb, Novartis

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS